China Touts New Drug for Alleviating COVID-19 Now Undergoing Trials

According to results of a comparative clinical trial published in the New England Journal of Medicine, VV116 is as effective as Paxlovid at curbing mild to moderate illness

Related Keywords

China ,London ,City Of ,United Kingdom ,Beijing ,Taiwan ,Shanghai ,United States ,Renji ,Henan ,Chinese ,American ,Amesh Adalja ,Junshi Biosciences ,Xu Huaqiang ,Shanghai Jiao Tong University School Of Medicine ,Gilead Sciences ,Viral Infections At Chang Gung University ,Us National Institutes Of Health ,Drug Administration ,Research Center ,Chinese Academy Of Sciences ,People Daily ,Shanghai Jiao Tong University ,China National Health Commission ,Pfizer ,Johns Hopkins Center ,Vigonvita Life Sciences ,Health Security ,Shanghai Institute Of Materia Medica ,New England Journal ,Shin Ru Shih ,Emerging Viral Infections ,Chang Gung University ,Shanghai Institute ,Materia Medica ,Chinese Academy ,National Health Commission ,Vigonvita Life ,Ruijin Hospital ,Renji Hospital ,Shanghai Jiao Tong University School ,China News ,Ovid 19 Pandemic ,Paxlovid ,Zero Covid Policy ,China Covid Reopening ,Vv116 ,